Latest Articles

Publication Date
The rising burden of endometrial cancer in Jamaica - Jamaica Observer

The rising burden of endometrial cancer in Jamaica Jamaica Observer

Published: June 21, 2026, 5:05 a.m.
MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial - MSN

MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial MSN

Published: June 21, 2026, 4:52 a.m.
Serum Interleukin-6 Levels in Endometriosis and Endometriosis-Associated Ovarian Cancer: A Systematic Review and Meta-Analysis Demonstrating a Biological Gradient.

This study quantifies serum/plasma interleukin-6 levels across the healthy-non-endometriosis benign-endometriosis-ovarian cancer spectrum, focusing on pooled geometric means stratified by control type.

Published: June 21, 2026, midnight
New NCCN Colorectal, Endometrial, Esophageal, and Gastric Cancer Guidlines Released - ICARE - Oncodaily

New NCCN Colorectal, Endometrial, Esophageal, and Gastric Cancer Guidlines Released - ICARE Oncodaily

Published: June 20, 2026, 5:02 p.m.
New NCCN Guidlines on Colorectal, Endometrial, Esophageal, and Gastric Cancer Released - ICARE - Oncodaily

New NCCN Guidlines on Colorectal, Endometrial, Esophageal, and Gastric Cancer Released - ICARE Oncodaily

Published: June 20, 2026, 5:02 p.m.
Dostarlimab Provides Long-Term Benefits in dMMR/MSI-H Endometrial Cancer - OncLive

Dostarlimab Provides Long-Term Benefits in dMMR/MSI-H Endometrial Cancer OncLive

Published: June 20, 2026, 1:04 p.m.
How AI imaging technique detects early endometrial cancer with accuracy - Medical Buyer

How AI imaging technique detects early endometrial cancer with accuracy Medical Buyer

Published: June 20, 2026, 10:17 a.m.
The role of anti-Müllerian hormone as a therapeutic agent to preserve the ovarian follicle pool during chemotherapy.

Cancer treatments can deplete the ovarian follicle reserve, causing infertility and early menopause, with subsequent decline in cardiovascular, cognitive, and overall women's health. Medical measures to prevent this chemotherapy-induced ovarian …

Published: June 20, 2026, midnight
Nivolumab Produces 68% Clinical CR Rate in Resectable dMMR Endometrial Cancer - OncLive

Nivolumab Produces 68% Clinical CR Rate in Resectable dMMR Endometrial Cancer OncLive

Published: June 19, 2026, 5:49 p.m.
Puxitatug Samrotecan Hits 60% Response Rate in Platinum- and IO-Pretreated Endometrial Cancer - Targeted Oncology

Puxitatug Samrotecan Hits 60% Response Rate in Platinum- and IO-Pretreated Endometrial Cancer Targeted Oncology

Published: June 19, 2026, 5:05 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!